Endoscopic scoring system utilization for inflammatory bowel disease activity assessment: A multicenter real-world study from Argentina

被引:0
|
作者
Lasa, Juan [1 ]
Smolarczuk, Astrid [2 ]
Navar, Sofia [2 ]
Ponce, Carla [2 ]
Galvarini, Martin [2 ]
Orellana, Daniel [2 ]
Caruso, Emiliano [2 ]
Espinosa, Federico [2 ]
Meligrana, Noelia [3 ]
Rainero, German [3 ]
Correa, Gustavo [4 ]
Yantorno, Martin [4 ]
Garbi, Maria [4 ]
Giraudo, Florencia [4 ]
Martinez, Soledad [1 ]
Garcia, Lucia [5 ]
Marceno, Florencia [5 ]
Marturano, Victoria [5 ]
Reyes, Kevin [6 ]
Steinberg, Leandro [5 ,6 ]
Pereyra, Lisandro [2 ,5 ]
Olivera, Pablo [1 ,7 ]
机构
[1] CEMIC, Gastroenterol Dept, Buenos Aires, Argentina
[2] Hosp Aleman, Gastroenterol Dept, Buenos Aires, Argentina
[3] Hosp Univ Austral, Gastroenterol Dept, Pilar, Argentina
[4] HIGA San Martin, Gastroenterol Dept, La Plata, Argentina
[5] Hosp Gen Agudos Carlos Durand, Gastroenterol Dept, Buenos Aires, Argentina
[6] Hosp Univ Fdn Favaloro, Gastroenterol Dept, Buenos Aires, Argentina
[7] Sinai Hlth Syst Gastroenterol, Zane Cohen Ctr Digest Dis, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源
GASTROENTEROLOGIA Y HEPATOLOGIA | 2024年 / 47卷 / 03期
关键词
Colonoscopy; Crohn's disease; Ulcerative colitis; CROHNS-DISEASE; COLITIS; INDEXES;
D O I
10.1016/j.gastrohep.2023.06.002
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The frequency and patterns of use of scores for the assessment of endoscopic activity in inflammatory bowel disease patients are not known. Aim: To describe the prevalence of adequate use of endoscopic scores in IBD patients who underwent colonoscopy in a real-life setting. Materials and methods: A multicenter observational study comprising six community hospitals in Argentina was undertaken. Patients with a diagnosis of Crohn's disease or ulcerative colitis who underwent colonoscopy for endoscopic activity assessment between 2018 and 2022 were included. Colonoscopy reports of included subjects were manually reviewed to determine the proportion of colonoscopies that included an endoscopic score report. We determined the pro- portion of colonoscopy reports that included all of the IBD colonoscopy report quality elements proposed by BRIDGe group. Endoscopist's specialty, years of experience as well as expertise in IBD were assessed. Results: A total of 1556 patients were included for analysis (31.94% patients with Crohn's disease). Mean age was 45.94 +/- 15.46. Endoscopic score reporting was found in 58.41% of colono- scopies. Most frequently used scores were Mayo endoscopic score (90.56%) , SES-CD (56.03%) for ulcerative colitis and Crohn's disease, respectively. In addition, 79.11% of endoscopic reports failed to comply with all recommendations on endoscopic reporting for inflammatory bowel disease. Conclusions: A significant proportion of endoscopic reports of inflammatory bowel disease patients do not include the description of an endoscopic score to assess mucosal inflammatory activity in a real -world setting. This is also associated with a lack of compliance in recommended criteria for proper endoscopic reporting. (c) 2023 Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:253 / 261
页数:9
相关论文
共 50 条
  • [11] Adalimumab Persistence and Its Biosimilar in Inflammatory Bowel Disease: A Real-World Study
    Fernandez-Cano, Maria Carmen
    Fernandez-Cano, Antonio Jesus
    Martin-Rodriguez, Maria Mar
    Sanchez-Capilla, Antonio Damian
    Cabello-Tapia, Maria Jose
    Redondo-Cerezo, Eduardo
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (02)
  • [12] Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY
    Cleveland, Noa Krugliak
    Ghosh, Sabyasachi
    Chastek, Benjamin
    Bancroft, Tim
    Candela, Ninfa
    Fan, Tao
    Umashankar, Kandavadivu
    Rubin, David T.
    INFLAMMATORY BOWEL DISEASES, 2023, 30 (10) : 1776 - 1787
  • [13] Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
    Hernandez-Camba, A.
    Arranz, L.
    Vera, I
    Carpio, D.
    Calafat, M.
    Lucendo, A. J.
    Taxonera, C.
    Marin, S.
    Garcia, M. J.
    Marin, G. Suris
    Rodriguez, E. Sanchez
    Carbajo, A. Y.
    De Castro, M. L.
    Iborra, M.
    Martin-Cardona, A.
    Rodriguez-Lago, I
    Busquets, D.
    Bertoletti, F.
    Ausin, M. Sierra
    Tardillo, C.
    Malaves, J. Huguet
    Bujanda, L.
    Castano, A.
    Domenech, E.
    Ramos, L.
    DIGESTIVE AND LIVER DISEASE, 2022, 54 (05) : 635 - 641
  • [14] The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease Patients
    Magro, Fernando
    Fernandes, Samuel
    Patita, Marta
    Arroja, Bruno
    Lago, Paula
    Rosa, Isadora
    de Sousa, Helena Tavares
    Ministro, Paula
    Mocanu, Irina
    Vieira, Ana
    Castela, Joana
    Moleiro, Joana
    Roseira, Joana
    Cancela, Eugenia
    Sousa, Paula
    Portela, Francisco
    Correia, Luis
    Moreira, Paula
    Dias, Sandra
    Afonso, Joana
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    Vucicevic, Katarina M.
    Santiago, Mafalda
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (07) : 1102 - 1112
  • [15] Real-world biologic treatment and associated cost in patients with inflammatory bowel disease
    Brandes, Alina
    Groth, Antje
    Gottschalk, Fraence
    Wilke, Thomas
    Ratsch, Boris A.
    Orzechowski, Hans-Dieter
    Fuchs, Andreas
    Deiters, Barthold
    Bokemeyer, Bernd
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2019, 57 (07): : 843 - 851
  • [16] Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil
    Zaltman, Cyrla
    Parra, Rogerio Serafim
    Sassaki, Ligia Yukie
    Santana, Genoile Oliveira
    Ferrari, Maria de Lourdes Abreu
    Miszputen, Sender J.
    Amarante, Heda M. B. S.
    Kaiser Junior, Roberto Luiz
    Flores, Cristina
    Catapani, Wilson R.
    Parente, Jose Miguel Luz
    Bafutto, Mauro
    Ramos, Odery
    Goncalves, Carolina D.
    Guimaraes, Isabella Miranda
    da Rocha, Jose J. R.
    Feitosa, Marley R.
    Feres, Omar
    Saad-Hossne, Rogerio
    Penna, Francisco Guilherme Cancela
    Cunha, Pedro Ferrari Sales
    Gomes, Tarcia N. F.
    Nones, Rodrigo Bremer
    Faria, Mikaell Alexandre Gouvea
    Parente, Mirian Perpetua Palha Dias
    Scotton, Antonio S.
    Caratin, Rosana Fusaro
    Senra, Juliana
    Chebli, Julio Maria
    WORLD JOURNAL OF GASTROENTEROLOGY, 2021, 27 (02) : 208 - 223
  • [17] Association Between Biologics and Janus Kinase Inhibitors With Inflammatory Bowel Disease as Paradoxical Reactions: A Real-World Assessment
    Zhan, Zhi-Qing
    Li, Jia-Xin
    Chen, Ying-Xuan
    Fang, Jing-Yuan
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2024,
  • [18] Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study
    Eriksson, Carl
    Rundquist, Sara
    Lykiardopoulos, Vyron
    Udumyan, Ruzan
    Karlen, Per
    Grip, Olof
    Soderman, Charlotte
    Almer, Sven
    Hertervig, Erik
    Marsal, Jan
    Gunnarsson, Jenny
    Malmgren, Carolina
    Delin, Jenny
    Strid, Hans
    Sjoberg, Mats
    Oberg, David
    Bergemalm, Daniel
    Hjortswang, Henrik
    Halfvarson, Jonas
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2021, 14
  • [19] Impact of COVID-19 Treatment on Real-World Outcomes in Inflammatory Bowel Disease
    Sahyoun, Laura C.
    Fetene, Jonathan
    Mcmillan, Chandler
    Protiva, Petr
    Al Bawardy, Badr
    Gaidos, Jill K. J.
    Proctor, Deborah
    DIGESTIVE DISEASES AND SCIENCES, 2024, 69 (05) : 1654 - 1660
  • [20] Real-World Persistency for Inflammatory Bowel Disease Biologics Using Patient Registry Data
    Goss Sawhney, Tia
    Dobes, Angela
    O'Charoen, Sirimon
    CROHNS & COLITIS 360, 2023, 5 (04)